Very low rate of MTCT in women on HAART in UK and Ireland who achieve viral suppression
1 April 2008. Related: Conference reports, Pregnancy.
Conference reports
Predictors of mother to child transmission among women initiating HAART in pregnancy in a South African cohort
1 April 2008. Related: Conference reports, Pregnancy.
Maternal and infant outcomes from the DREAM programme
1 April 2008. Related: Conference reports, Pregnancy.
Nevirapine-resistant HIV present in the latent reservoir following single-dose nevirapine for MTCT prevention
1 April 2008. Related: Conference reports, Pregnancy.
Tenofovir plus FTC reduce NNRTI resistance following single dose nevirapine
1 April 2008. Related: Conference reports, Pregnancy.
Response to treatment after single dose NVP exposure in women
1 April 2008. Related: Conference reports, Pregnancy.
Response to treatment after single dose NVP exposure in infants
1 April 2008. Related: Conference reports, Pregnancy.
Other studies looking at birth outcomes
1 April 2008. Related: Conference reports, Pregnancy.
Infant prophylaxis for postnatal transmission
1 April 2008. Related: Conference reports, Pregnancy.
Antiretroviral drug concentrations in breast milk and breastfeeding infants
1 April 2008. Related: Conference reports, Pregnancy.
Maternal breastfeeding prophylaxis
1 April 2008. Related: Conference reports, Pregnancy.
Risk factors for breastfeeding transmission
1 April 2008. Related: Conference reports, Pregnancy.
UK cohort reports sexual HCV reinfection in at least 5% HIV-positive gay men following sustained response to treatment
1 April 2008. Related: Conference reports, Hepatitis coinfection.
MELD score predictive of pre-transplant mortality in HCV coinfected patients
1 April 2008. Related: Conference reports, Hepatitis coinfection.
Does abacavir decrease SVR rates with HCV treatment?
1 April 2008. Related: Conference reports, Hepatitis coinfection.
No effect of interferon maintenance therapy on fibrosis progression in non-responders
1 April 2008. Related: Conference reports, Hepatitis coinfection.
Stem cell transplant from HLA-matched CCR5-delta 32 deleted donor suppresses viraemia in recipient for 8 months without HAART
1 April 2008. Related: Conference reports, Basic science and immunology.
Risk factors for AIDS-defining and non AIDS-defining cancers
1 April 2008. Related: Conference reports, Cancer and HIV.
CROI 2008 – 12 key areas of research: non-technical summary of 25 studies and presentations
28 February 2008. Related: Special reports, Conference reports.
15th Conference on Retroviruses and Opportunistic Infections, 2-6 February 2008, Boston
1 February 2008. Related: Conference reports.
Increased risk of myocardial infarction associated with abacavir and ddI
1 February 2008. Related: Conference reports.
Position statement by the D:A:D steering committee
1 February 2008. Related: Conference reports.
3rd International Workshop on Targeting HIV Entry, 7-9 December 2007, Washington DC
1 February 2008. Related: Conference reports.
CXCR4-using HIV found in 8.5% during early HIV infection
1 February 2008. Related: Conference reports.
Background drugs and low maraviroc levels explain resistance in Motivate studies
1 February 2008. Related: Conference reports, Drug resistance.
38th World Conference on Lung Health of the Union Against TB and Lung Disease, December 2007, Cape Town
1 February 2008. Related: Conference reports.
Treatment outcomes in patients who received rifampicin with nevirapine or efavirenz
1 February 2008. Related: Conference reports, TB coinfection.
11th European AIDS conference (EACS), October 24-27 2007, Madrid
2 December 2007. Related: Conference reports.
New European guidelines launched (2007)
2 December 2007. Related: Conference reports, Guidelines.
Saquinavir/r non-inferior to Kaletra at week 48 (Gemini study)
2 December 2007. Related: Conference reports, Antiretrovirals.
Darunavir once-daily is non-inferior to lopinavir/r in treatment-naive patients at 48 weeks (Artemis study)
2 December 2007. Related: Conference reports, Antiretrovirals.
Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results
2 December 2007. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Drug interaction studies presented at EACS
1 December 2007. Related: Conference reports, PK and drug interactions, Basic science and immunology.
BHIVA Autumn conference, 11-12 October 2007, London
29 October 2007. Related: Conference reports.
Audit of treating naive patients showed basic UK guidelines not followed in over 25% patients; 60% patients start with a CD4 count <200 cells/mm3
2 October 2007. Related: Conference reports.
4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney
3 September 2007. Related: Conference reports.
HIV viraemia may explain increased risk of cardiovascular disease, death and other serious events in people interrupting treatment in the SMART trial: new study to randomise people with CD4 counts >500 to start immediate treatment or defer to <350 cells/mm3
3 September 2007. Related: Conference reports, Treatment strategies.
CD4 increases in immunological non-responders despite suppressive therapy following switch to nuke-sparing regimen of ATZ/SQV/r
3 September 2007. Related: Conference reports, Treatment strategies.
Darunavir/r shows superiority over lopinavir/r at 48 weeks in TITAN trial
3 September 2007. Related: Conference reports, Antiretrovirals.
Maraviroc fails to show non-inferiority to efavirenz in treatment-naive patients: 48 week results
3 September 2007. Related: Conference reports, Antiretrovirals.
Importance of using maraviroc in combination with other active drugs in treatment-experienced patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Week 48 raltegravir results in treatment-naive phase II dose-finding study
3 September 2007. Related: Conference reports, Antiretrovirals.
DUET studies clarify antiviral efficacy of etravirine and cross-resistance profile to other NNRTIs
3 September 2007. Related: Conference reports, Antiretrovirals.
Boosting atazanavir in treatment-naive patients, and impact on lipids after switching from lopinavir/r
3 September 2007. Related: Conference reports, Antiretrovirals.
Saquinavir/r vs lopinavir/r in treatment-naive patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Fosamprenavir/r vs atazanvir/r in treatment-naive patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young infants; interim results from the CHER study
3 September 2007. Related: Conference reports, Paediatric care.
Very low transmission rates among breastfeeding women receiving ART
3 September 2007. Related: Conference reports, Pregnancy.
Use of pre-exposure prophylaxis (PrEP) by sero-different couples wanting to conceive a child
3 September 2007. Related: Conference reports, Pregnancy.
Increased incidence of miscarriage with efavirenz use
3 September 2007. Related: Conference reports, Pregnancy.
No impact of HSV-2 suppressive therapy on HIV incidence
3 September 2007. Related: Conference reports.
Penile washing directly after sex increased the risk of acquiring HIV: circumcision effective for men in high prevalence populations no protective effect in gay men
3 September 2007. Related: Conference reports.
HBV or HCV coinfection produced higher risk from treatment interruptions: drug holidays and hepatitis dont mix
3 September 2007. Related: Conference reports, Hepatitis coinfection.
9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 19-21 July 2007, Sydney
3 September 2007. Related: Conference reports.
Can nevirapine be safely substituted for other agents in those with high CD4 cell counts and virologic suppression?
3 September 2007. Related: Conference reports.
Do children with perinatally acquired HIV infection have problems with metabolism and body shape?
3 September 2007. Related: Conference reports.
The growth hormone releasing factor analogue tesamorelin (TH9507) reduces visceral fat, but what else does it do?
3 September 2007. Related: Conference reports.
Does diabetes have the same impact on cardiovascular risk in HIV-positive patients as it does in the general population?
3 September 2007. Related: Conference reports.
Can nucleoside RT inhibitors directly cause insulin resistance?
3 September 2007. Related: Conference reports.
Do dyslipidemia, insulin resistance, and body shape changes differ according to race or ethnicity?
3 September 2007. Related: Conference reports.
Is lipoatrophy associated with vascular dysfunction?
3 September 2007. Related: Conference reports.
XVI International HIV Drug Resistance Workshop, 12-16 June 2007, Barbados
7 July 2007. Related: Conference reports.
Integrase inhibitors and resistance
7 July 2007. Related: Conference reports, Drug resistance.
Treatment failure and tropism changes in maraviroc trial related to previously undetected CXCR4, rather than a mutational shift from CCR5
3 July 2007. Related: Conference reports, Drug resistance.
Mechanisms of failure to CCR5 inhibitors is not explained by mutation in the V3 loop, cross-resistance between CCR5 inhibitors is likely
3 July 2007. Related: Conference reports, Drug resistance.